Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Metrics to compare | ALSEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALSENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.0x | −3.1x | −0.4x | |
PEG Ratio | 0.98 | −0.05 | 0.00 | |
Price/Book | 4.6x | 0.2x | 2.6x | |
Price / LTM Sales | 35.4x | 12.2x | 3.2x | |
Upside (Analyst Target) | 176.3% | 191.7% | 50.6% | |
Fair Value Upside | Unlock | 3.0% | 6.6% | Unlock |